{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Carcinoma&page=35", "query": { "condition": "Neuroendocrine Carcinoma", "page": 35 }, "page_size": 10 }, "pagination": { "page": 35, "page_size": 10, "total_count": 946, "total_pages": 95, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Carcinoma&page=36&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Carcinoma&page=34&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T08:41:57.118Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03228667", "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer", "Small Cell Lung Cancer", "Urothelial Carcinoma", "Head and Neck Squamous Cell Carcinoma", "Merkel Cell Carcinoma", "Melanoma", "Renal Cell Carcinoma", "Gastric Cancer", "Cervical Cancer", "Hepatocellular Carcinoma", "Microsatellite Instability", "Mismatch Repair Deficiency", "Colorectal Cancer" ], "interventions": [ { "name": "N-803 + Pembrolizumab", "type": "DRUG" }, { "name": "N-803 + Nivolumab", "type": "DRUG" }, { "name": "N-803 + Atezolizumab", "type": "DRUG" }, { "name": "N-803 + Avelumab", "type": "DRUG" }, { "name": "N-803 + Durvalumab", "type": "DRUG" }, { "name": "N-803 + Pembrolizumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Nivolumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Atezolizumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Avelumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Durvalumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Docetaxel + Pembrolizumab", "type": "DRUG" }, { "name": "N-803 + Docetaxel + Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2018-12-11", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-01-14", "last_synced_at": "2026-10-16T08:41:57.118Z", "location_count": 35, "location_summary": "Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 31 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "El Segundo", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03228667" }, { "nct_id": "NCT06022029", "title": "A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Triple Negative Breast Cancer", "Diffuse Large B Cell Lymphoma", "Follicular Lymphoma", "Lymphoma, Non-Hodgkin", "Mantle Cell Lymphoma", "Bladder Cancer", "Uveal Melanoma, Recurrent", "Cervix Cancer", "Carcinoma in Situ", "Head and Neck Squamous Cell Carcinoma", "Skin Cancer", "Metastatic Cancer", "Tumor, Solid", "Tumor Recurrence" ], "interventions": [ { "name": "ONM-501", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoNano Medicine, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 168, "start_date": "2023-10-13", "completion_date": "2026-08-29", "has_results": false, "last_update_posted_date": "2025-12-24", "last_synced_at": "2026-10-16T08:41:57.118Z", "location_count": 9, "location_summary": "Los Angeles, California • Tamarac, Florida • Canton, Ohio + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tamarac", "state": "Florida" }, { "city": "Canton", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06022029" }, { "nct_id": "NCT07836712", "title": "Multiple Adjunct Therapies to Improve Immunotherapy Treatment in Patients With Locally Advanced or Metastatic Melanoma or Advanced Hepatocellular Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Hepatocellular Carcinoma", "Advanced Melanoma", "Locally Advanced Melanoma", "Metastatic Melanoma", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cholecalciferol", "type": "DIETARY_SUPPLEMENT" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Desloratadine", "type": "DRUG" }, { "name": "Immunotherapy", "type": "OTHER" }, { "name": "Infusion Procedure", "type": "PROCEDURE" }, { "name": "Magnesium Sulfate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Propranolol", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DIETARY_SUPPLEMENT", "DRUG", "OTHER" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2026-11-01", "completion_date": "2028-11-01", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-16T08:41:57.118Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07836712" }, { "nct_id": "NCT02543645", "title": "A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Renal Cell", "Kidney Diseases", "Kidney Neoplasms", "Urogenital Neoplasms", "Urologic Diseases", "Urologic Neoplasms", "Neoplasms by Histologic Type", "Neoplasms", "Clear-cell Metastatic Renal Cell Carcinoma", "Melanoma", "Triple Negative Breast Cancer", "Bladder Cancer", "Head and Neck Cancer", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Combination of Varlilumab and Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2015-10", "completion_date": "2017-05-22", "has_results": false, "last_update_posted_date": "2018-04-30", "last_synced_at": "2026-10-16T08:41:57.118Z", "location_count": 4, "location_summary": "San Francisco, California • Boston, Massachusetts • New York, New York + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02543645" }, { "nct_id": "NCT03271372", "title": "Adjuvant Avelumab in Merkel Cell Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage III Merkel Cell Carcinoma AJCC v8", "Stage IIIB Merkel Cell Carcinoma AJCC v8", "Stage IIIA Merkel Cell Carcinoma AJCC v8" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Peripheral Blood Collection", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2017-12-19", "completion_date": "2029-02-18", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-10-16T08:41:57.118Z", "location_count": 9, "location_summary": "Orange, California • Aurora, Colorado • Tampa, Florida + 6 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03271372" }, { "nct_id": "NCT00843531", "title": "RAD001 and Erlotinib in Patients With Neuroendocrine Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroendocrine Tumors" ], "interventions": [ { "name": "RAD001", "type": "DRUG" }, { "name": "erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2009-06-25", "completion_date": "2016-08-20", "has_results": true, "last_update_posted_date": "2020-09-29", "last_synced_at": "2026-10-16T08:41:57.118Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00843531" }, { "nct_id": "NCT01351103", "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer", "BRAF Mutant Colorectal Cancer", "Melanoma", "Triple Negative Breast Cancer", "Head and Neck Squamous Cell Cancer", "Cervical Squamous Cell Cancer", "Esophageal Squamous Cell Cancer", "Lung Squamous Cell Cancer" ], "interventions": [ { "name": "LGK974", "type": "DRUG" }, { "name": "PDR001", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 185, "start_date": "2011-12-01", "completion_date": "2024-06-17", "has_results": false, "last_update_posted_date": "2025-06-13", "last_synced_at": "2026-10-16T08:41:57.118Z", "location_count": 6, "location_summary": "Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01351103" }, { "nct_id": "NCT00112476", "title": "Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Melanoma", "Recurrent Renal Cell Cancer", "Stage IV Melanoma", "Stage IV Renal Cell Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "bryostatin 1", "type": "DRUG" }, { "name": "temsirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2005-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-05-03", "last_synced_at": "2026-10-16T08:41:57.118Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00112476" }, { "nct_id": "NCT04284774", "title": "Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Solid Neoplasm", "Recurrent Adrenal Gland Pheochromocytoma", "Recurrent Ectomesenchymoma", "Recurrent Ependymoma", "Recurrent Ewing Sarcoma", "Recurrent Hepatoblastoma", "Recurrent Kidney Wilms Tumor", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Malignant Germ Cell Tumor", "Recurrent Malignant Glioma", "Recurrent Medulloblastoma", "Recurrent Melanoma", "Recurrent Neuroblastoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Osteosarcoma", "Recurrent Peripheral Primitive Neuroectodermal Tumor", "Recurrent Rhabdoid Tumor", "Recurrent Rhabdoid Tumor of the Kidney", "Recurrent Rhabdomyosarcoma", "Recurrent Soft Tissue Sarcoma", "Recurrent Thyroid Gland Carcinoma", "Recurrent WHO Grade 2 Glioma", "Refractory Adrenal Gland Pheochromocytoma", "Refractory Ependymoma", "Refractory Ewing Sarcoma", "Refractory Hepatoblastoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Malignant Germ Cell Tumor", "Refractory Malignant Glioma", "Refractory Medulloblastoma", "Refractory Melanoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Refractory Peripheral Primitive Neuroectodermal Tumor", "Refractory Rhabdoid Tumor", "Refractory Rhabdoid Tumor of the Kidney", "Refractory Rhabdomyosarcoma", "Refractory Soft Tissue Sarcoma", "Refractory Thyroid Gland Carcinoma", "Refractory WHO Grade 2 Glioma" ], "interventions": [ { "name": "Tipifarnib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 5, "start_date": "2020-10-13", "completion_date": "2027-09-30", "has_results": true, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-10-16T08:41:57.118Z", "location_count": 171, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04284774" }, { "nct_id": "NCT03370861", "title": "How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Autoimmunity", "Melanoma", "Merkel Cell Carcinoma", "Squamous Cell Carcinoma of the Skin", "Basal Cell Carcinoma", "Skin Cancer" ], "interventions": [ { "name": "Immunotherapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2017-11-08", "completion_date": "2022-12-31", "has_results": false, "last_update_posted_date": "2024-09-05", "last_synced_at": "2026-10-16T08:41:57.118Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03370861" } ] }